PD-0482: Early breast cancer treated with an electronic IORT system: report of the first patients treated in Portugal

Costa, P.; Oliveira, Fernanda; Fonseca, G.; Costa, Alves da; Moutinho, J.; Ribeiro, M. S.; Vale, João R.; Ponte, Fernanda

doi:10.1016/s0167-8140(15)40478-5

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study of Dickler [15], overall cosmetics are rated as excellent in 88% of patients. Costa [14] reports only mild skin reactions without any grade 3/4 acute toxicity or delayed healing. In the study of Chowdhry [18], 92.1% of patients have been very pleased with the cosmetics.…”

Section: Resultsmentioning

confidence: 99%

Intraoperative Radiotherapy with Balloon-Based Electronic Brachytherapy System—A Systematic Review and First Bulgarian Experience in Breast Cancer Patients

et al. 2021

View full text Add to dashboard Cite

(1) Background: We aimed to analyze currently available studies with intraoperative radiotherapy (IORT) as a choice of treatment where the Xoft Axxent® electronic brachytherapy (eBx) system was used as a single-dose irradiation and an exclusive radiotherapy approach at the time of surgery in patients with early breast cancer (EBC). We also compared the results of the systematic review to the Bulgarian experience. (2) Methods and Materials: We performed a systematic review of the studies published before February 2021, which investigate the application of a single-fraction 20 Gy radiation treatment, delivered at the time of lumpectomy in EBC patients with the Xoft Axxent® eBx System. A systematic search in PubMed, Scopus, and ScienceDirect was performed. The results are reported following the PRISMA guidelines. The criteria on patients’ selection for IORT (the additional need for EBRT), cosmetic outcomes, and recurrence rate from the eligible studies are compared to the treatment results in Bulgarian patients. (3) Results: We searched through 1032 results to find 17 eligible studies. There are no published outcomes from randomized trials. When reported, the cosmetic outcomes in most of the studies are defined as excellent. The observed recurrence rate is low (1–5.8%). Still, the number of patients additionally referred to postoperative external breast radiotherapy (EBRT) is up to 31%. Amongst the 20 patients treated in Bulgaria, the cosmetic outcomes are also evaluated as excellent, five of which (25%) are referred for EBRT. Within median follow-up of 39 months, there was one local and one distal recurrence. (4) Conclusions: Current evidence demonstrates the Xoft Axxent® eBx system as a safe and feasible technique for IORT delivery in EBC patients. There are no randomized controlled trials conducted at this time point to prove its long-term effectiveness. Better patient selection and a reimbursement strategy have to be proposed to extend the application of this technique in Bulgaria.

show abstract

Section: Resultsmentioning

confidence: 99%

Intraoperative Radiotherapy with Balloon-Based Electronic Brachytherapy System—A Systematic Review and First Bulgarian Experience in Breast Cancer Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Another Israeli study of 158 women showed excellent results, with no local recurrence after 30 months [ 21 ]. Other studies of varying sample sizes have reported local recurrence rates between 1% and 5.8% [ 22 – 26 ].…”

Section: Discussionmentioning

confidence: 99%

Application of Intraoperative Radiotherapy in Early‐Stage Breast Cancer Patients in a Clinical Setting

Wang,

Quint,

Kukeev

et al. 2024

International Journal of Breast Cancer

View full text Add to dashboard Cite

Background: Intraoperative radiation therapy (IORT) has gained popularity in recent years as an alternative to external beam whole breast radiation therapy (WBRT) for early‐stage breast cancer. Here, we report 43‐month recurrence and survival outcomes in a multiethnic cohort treated with IORT in a clinical context.Method: Two hundred and eleven patients with low‐risk features were treated with IORT for early‐stage breast cancer from 2014 to 2021. Selection criteria were based on Group Europeen de Curietherapie‐European Society for Therapeutic Radiology and Oncology (GEC‐ESTRO) guidelines: preferably unifocal intraductal carcinoma (IDC), aged > 50, tumor size ≤ 2.0 cm, and without lymph node involvement. All patients received 20 Gy of radiation dose during the lumpectomy. Information on patient and tumor characteristics was collected.Results: The mean age of this cohort was 67.5 years; 95.2% of patients are Jewish, and the rest are Bedouins (4.7%). Most tumors were intraductal carcinoma (97.2%) and stage 1 (94.8%). The mean follow‐up time was 43.4 months. Bedouins had larger tumor sizes (mean 1.21 vs. 1.13 cm) and were younger at diagnosis than Jewish patients (mean 65.4 vs. 67.6 years), although the differences are not significant. The overall recurrence rate was 1.4%. One case of local recurrence (0.5%) and two cases of metastasis (0.9%) were observed during the study period. One patient died from metastasis.Conclusion: Our findings suggest that IORT in selected low‐risk patients can achieve an excellent prognosis with low rates of recurrence and metastasis.

show abstract

PD-0482: Early breast cancer treated with an electronic IORT system: report of the first patients treated in Portugal

Cited by 2 publications

References 0 publications

Intraoperative Radiotherapy with Balloon-Based Electronic Brachytherapy System—A Systematic Review and First Bulgarian Experience in Breast Cancer Patients

Intraoperative Radiotherapy with Balloon-Based Electronic Brachytherapy System—A Systematic Review and First Bulgarian Experience in Breast Cancer Patients

Application of Intraoperative Radiotherapy in Early‐Stage Breast Cancer Patients in a Clinical Setting

Contact Info

Product

Resources

About